|
|
|
|
| LEADER |
01942nam a2200325 u 4500 |
| 001 |
EB001999959 |
| 003 |
EBX01000000000000001162860 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.)
|h Elektronische Ressource
|b indication : treatment of neovascular (wet) age-related macular degeneration (nAMD)
|
| 246 |
3 |
1 |
|a Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.)
|
| 250 |
|
|
|a Version: 1
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, May 2020
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Wet Macular Degeneration / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK565314
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6 mg (0.05 mL) administered by intravitreal injection every four weeks for the first three doses, after which it can be given as one injection every 12 weeks in patients without disease activity or one injection every eight weeks in patients with disease activity, based on the physician assessment
|